Stock 2269 WUXI BIOLOGICS (CAYMAN) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:13 2024-04-23 am EDT 		5-day change 1st Jan Change
12.98 HKD +1.41% Intraday chart for WuXi Biologics (Cayman) Inc. -4.42% -56.15%
Apr. 01 Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer CI
Mar. 27 WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump MT

Business Summary

WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.

Number of employees: 12,740

Sales per Business

HKD in Million2021Weight2022Weight Delta
Research Services on Fee-for-Service
83.6 %
9,684 78.1 % 14,838 83.6 % +53.22%
Biologics Product
14.5 %
- - 2,582 14.5 % -
Research Services on Full-Time-Equivalent
1.7 %
290 2.3 % 309 1.7 % +6.56%
Project Management Organization Services
0.1 %
22 0.2 % 26 0.1 % +20.48%

Sales per region

HKD in Million2021Weight2022Weight Delta
North America
55.6 %
6,302 50.8 % 9,880 55.6 % +56.78%
China
24.4 %
3,026 24.4 % 4,325 24.4 % +42.92%
Europe
16.7 %
2,743 22.1 % 2,961 16.7 % +7.93%
Rest of the World
3.3 %
330 2.7 % 590 3.3 % +78.45%

Managers

Managers TitleAgeSince
Zhi Sheng Chen CEO
 Chief Executive Officer 52 11-05-31
Ming Tu DFI
 Director of Finance/CFO 54 21-08-22
Gu Jijie CTO
 Chief Tech/Sci/R&D Officer 57 -
Weichang Zhou BRD
 Director/Board Member 59 12-11-30
Yue Huang SEC
 Corporate Secretary - 18-11-19
Ying Man Sham SEC
 Corporate Secretary - -

Members of the board

Members of the board TitleAgeSince
Jackson Tai BRD
 Director/Board Member 73 23-05-05
William Keller BRD
 Director/Board Member 75 17-05-16
Ge Li CHM
 Chairman 56 10-04-30
Yan Ling Cao BRD
 Director/Board Member 39 16-04-30
Yi Bing Wu BRD
 Director/Board Member 55 16-04-30
Zhi Sheng Chen CEO
 Chief Executive Officer 52 11-05-31
Weichang Zhou BRD
 Director/Board Member 59 12-11-30
Kenneth Hitchner BRD
 Director/Board Member 63 20-06-08
Jue Chen BRD
 Director/Board Member 54 23-08-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,259,275,169 3,655,172,375 ( 85.82 %) 0 85.82 %

Shareholders

NameEquities%Valuation
Wuxi Biologics Holdings Ltd.
13.86 %
590,257,633 13.86 % 1 078 M $
Biologics Holdings
13.72 %
584,191,133 13.72 % 1 067 M $
Capital Research & Management Co. (World Investors)
4.754 %
202,451,467 4.754 % 370 M $
BlackRock Fund Advisors
1.636 %
69,651,000 1.636 % 127 M $
BlackRock Advisors (UK) Ltd.
1.061 %
45,162,865 1.061 % 83 M $
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)
0.7512 %
31,988,135 0.7512 % 58 M $
Zhong Ou Asset Management Co., Ltd
0.6717 %
28,605,169 0.6717 % 52 M $
JPMorgan Investment Management, Inc.
0.6706 %
28,555,149 0.6706 % 52 M $
Bank of Communications Schroder Fund Management Co., Ltd.
0.6209 %
26,440,738 0.6209 % 48 M $
JPMorgan Asset Management (Asia Pacific) Ltd.
0.5091 %
21,679,639 0.5091 % 40 M $
NameEquities%Valuation
RhumbLine Advisers LP
0.000777 %
16,549 0.000777 % 59 411 $
Lumyna Investments Ltd.
0.000195 %
4,160 0.000195 % 14 934 $
PNC Investments LLC
0.000073 %
1,558 0.000073 % 5 593 $
Ramirez Asset Management, Inc.
0.000020 %
436 0.000020 % 1 565 $
GAMMA Investing LLC
0.000000 %
6 0.000000 % 22 $

Company contact information

Wuxi Biologics (Cayman), Inc.

108, Meiliang Road Mashan

214092, Wuxi

+

http://www.wuxibiologics.com
address WuXi Biologics (Cayman) Inc.(2269)

Group companies

NameCategory and Sector
WuXi Biologics (Hong Kong) Ltd.

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sales per region

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
11.83 CNY
Average target price
27.49 CNY
Spread / Average Target
+132.34%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
-56.15% 6.8B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.49% 96.73B
ARGENX SE Stock argenx SE
-0.15% 21.31B
BIONTECH SE Stock BioNTech SE
-16.61% 21.21B
GENMAB A/S Stock Genmab A/S
-5.43% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.14% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-27.40% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.44% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.29% 10.98B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-21.79% 8.56B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2269 Stock
  4. Company WuXi Biologics (Cayman) Inc.